Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People who have been diagnosed with prostate cancer confirmed through laboratory testing of tissue samples
- People who have prostate cancer that has spread to other parts of the body, with at least one affected area visible on standard scans (such as CT, MRI, bone scan, PET/CT, or ultrasound)
- People whose doctors are considering starting or changing treatment to include a PARP inhibitor, hormone therapy, chemotherapy, or a combination of these — either as part of a clinical trial or standard medical care
- People who are willing to be informed about the research nature of the study and to sign a consent form agreeing to take part
Who may not be able to join:
- People who, in the opinion of a doctor involved in the trial, are unable to tolerate the imaging procedures required by the study
- People who have a current medical condition or illness that a trial doctor believes could affect their safety or their ability to successfully participate in the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Neil Taunk, MD, University of Pennsylvania
Phone: 215-573-6569
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Measurement of effect size
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.